<img src="https://www.bostonherald.com/wp-content/uploads/2018/11/HeraldDotComBanner.svg" alt="Boston Herald">

IDEXX Laboratories sees its Relative Strength Rating reach the 80-plus level.

IDEXX Laboratories Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

January 09, 2023

For a growth-oriented choice for the new year, I'm going with under-the-radar company, Catalyst Pharmaceuticals. Let's take a look at the company's fundamentals, technicals, and institutional support...

Top Picks For 2023: Catalyst Pharmaceuticals - Sunday, Jan. 8 ↗

January 08, 2023

Via Talk Markets

Top Picks For 2023: Catalyst Pharmaceuticals ↗

January 02, 2023

Catalyst Pharmaceuticals is a small-cap biopharma company focused on in-licensing, developing, and commercializing novel medicines to treat rare diseases. Let's take a closer look to see why it's a top...

Via Talk Markets

HC Wainwright & Co. Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know ↗

December 21, 2022

Via Benzinga

Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug ↗

December 20, 2022

Via Benzinga

Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

December 15, 2022

Via Benzinga

Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd

December 19, 2022

It's practically printing cash, and even more is on the way.

This Growth Stock's Jaw-Dropping Run-Up Is Smashing Tesla's ↗

December 16, 2022

Via The Motley Fool

Moderna Stock Shows Surprising Strength; Key Rating Upgraded ↗

December 14, 2022

See if Moderna stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day average.

Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.

Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗

November 29, 2022

Best Buy, Abercrombie & Fitch, Burlington Stores And Some Other Big Stocks Moving Higher On Tuesday ↗

November 22, 2022

U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Stock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review ↗

November 11, 2022

Bitcoin hit a two-year low while Meta and Tesla were in focus.

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

November 11, 2022

The company sells one drug, a treat for a rare muscle contraction condition.

Catalyst Pharma, The No. 1 IBD 50 Stock, Just Trounced Third-Quarter Expectations ↗

November 09, 2022

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

November 09, 2022

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

November 07, 2022

Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test.

Can Mid-Cap Lantheus Continue its 2022 Outperformance?

October 28, 2022

Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022

Topics ETFs Initial Public Offering

October 25, 2022

Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET

Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.

These 3 Stocks Are Winning the Bear Market -- Here's How ↗

October 21, 2022

Via The Motley Fool

Amgen Stock Shows Market Leadership With Jump To 90 RS Rating ↗

October 12, 2022

On Wednesday, Amgen stock hit a key technical milestone, with its Relative Strength Rating upgraded to 90, a rise from 78 the day before.

On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93.

BioCryst Pharmaceuticals Stock Shows Rising Relative Strength ↗

October 10, 2022

Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.

Small-Cap Catalyst Pharma Is Among Market's Best Price Performers

October 04, 2022

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients

Topics Stocks

September 29, 2022

FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S.

Intercept Pharmaceutical shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Intercept Pharmaceutical Stock Sees RS Rating Rise To 91 ↗

September 27, 2022

Pain Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.

Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating ↗

September 23, 2022

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year ↗

September 19, 2022

The biotech run off a June bottom is great — until you realize you could've netted more.

U.S. stock futures traded lower this morning after recording losses in the previous session. Here are some big stocks recording losses in today’s pre-market trading session.

FedEx, UPS And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗

September 16, 2022

Via Benzinga

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99.

Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90 ↗

September 14, 2022